Last reviewed · How we verify
NCT05263466
Establishing Radiolabelled PSMA as a Target for Glioma Treatment
NA trial testing PET-MRI in Glioma, Malignant in 30 participants. Not yet recruiting.
1 May 2027
Quick facts
| Lead sponsor | King's College Hospital NHS Trust |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 1 August 2022 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 May 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- PET-MRI — full drug profile →
- Brain tumour biopsy
Conditions studied
- Glioma, Malignant — all drugs for Glioma, Malignant →
Sponsor
King's College Hospital NHS Trust
Who can join
18 and older, any sex, with Glioma, Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study is being performed to observe whether a novel type of brain imaging using a technique called PET-MRI may provide useful information in the 'mapping' of adult primary brain tumours. It employs a radiolabelled molecule targeting a particular molecule called PSMA which is hypothesised to be a marker of aggression in primary brain tumours. 'Mapping' of the concentration and distribution of this molecule within brain tumours via PET-MRI may provide vital clinical information regarding the extent and timing of treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review.
Dall' Armellina S, Aghakhanyan G, Rizzo A, Fanni SC, et al · · 2025 · cited 2× · PMID 40165900 · DOI 10.3389/fonc.2025.1553505
Verify or expand the search:
- PubMed search for NCT05263466
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET-MRI
Trials testing the same drug.
- NCT05390814 — [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma · Phase 1 · completed
- NCT05772481 — Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcin · unknown
- NCT03549559 — Imaging Histone Deacetylase in the Heart · NA · recruiting
- NCT03342378 — PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients · completed
- NCT03252990 — 18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability · completed
Other recruiting trials for Glioma, Malignant
Currently open trials in the same condition.
- NCT06917885 — CUE-102 in Recurrent Glioblastoma · Phase 1 · recruiting
- NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
- NCT06169280 — Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma · Phase 1 · recruiting
- NCT06636162 — Window of Opportunity Study of DSP-0390 in Gliomas · EARLY_PHASE1 · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other King's College Hospital NHS Trust trials
Trials by the same sponsor.
- NCT07384884 — Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas · NA · not yet recruiting
- NCT07379723 — Brief Intervention for FCD: A Feasibility Study · NA · recruiting
- NCT07062731 — Pelvic Floor Exercises for Suboptimal Anorectal Manometry · recruiting
- NCT06766162 — Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection · NA · completed
- NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05263466 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by King's College Hospital NHS Trust
- Last refreshed: 10 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05263466.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing